Zuppa Antonio A, Cardiello Valentina, Alighieri Giovanni, Cota Francesco, D'Antuono Annamaria, Riccardi Riccardo, Catenazzi Piero, Romagnoli Costantino
Department of Pediatrics, Division of Neonatology, Catholic University of the Sacred Heart, Rome, Italy.
J Pediatr Hematol Oncol. 2013 Aug;35(6):e269-71. doi: 10.1097/MPH.0b013e318271f5b0.
The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.
